)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Aardvark Therapeutics (AARD) investor relations material
Aardvark Therapeutics Evercore ISI 8th Annual HealthCONx Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Evercore ISI 8th Annual HealthCONx Conference summary4 Dec, 2025
Technology overview
Oral small molecule drug is gut-restricted, activating gut-brain signaling via the vagus nerve to regulate hunger by inducing gut peptide hormone release through GPCR engagement on enteroendocrine cells.
Single agent (ARD-101) targets rare disease; combination with Sitagliptin is for general obesity, leveraging mechanistic rationale for both.
ARD-101 engages bitter taste receptors in the gut, stimulating hormone release that signals satiety to the brain.
Combination with Sitagliptin prolongs the activity of gut hormones by inhibiting DPP-4, enhancing anti-appetite effects.
Drug formulation avoids taste issues by releasing contents only in the gut.
Clinical data and development status
Monotherapy showed 1.3 kg weight loss over 28 days in a phase 2 obesity study without diet or exercise; comparable to Semaglutide's 1.6 kg in similar timeframe.
Combination therapy demonstrated 19% body weight loss in high-fat-fed mouse model, nearly matching Tirzepatide's 20.5%.
No clinical data yet for the combination in humans; the POWER trial will address this.
Phase 3 HERO trial in Prader-Willi syndrome began dosing in Q2 2024, with top-line data expected Q3 2026.
Competitive landscape and differentiation
ViCat (diazoxide choline) is a recent competitor, approved for hyperphagia but has exclusions for renal insufficiency and risk of hyperglycemia.
ARD-101 does not have renal exclusions and may improve insulin sensitivity, based on clinical and preclinical data.
Both drugs use the same HQ-CT9 endpoint for hyperphagia; even a one-point reduction is considered clinically meaningful.
ARD-101 is not mutually exclusive with ViCat and may be suitable for patients unable to tolerate ViCat.
PWS: ARD-101's differentiation vs. ViCat
Obesity combo: clinical trial strategy
PWS: ARD-101's impact on other symptoms
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Aardvark Therapeutics earnings date
Q4 202531 Mar, 2026
Next Aardvark Therapeutics earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Aardvark Therapeutics Inc is a U.S.-based biotechnology company focused on the development of small molecule therapeutics for the treatment of metabolic and inflammatory diseases. The company engages in research and clinical development aimed at modulating specific biological pathways to address unmet medical needs. Aardvark Therapeutics operates through internal R&D efforts and collaborations with academic and industry partners. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage